+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 134 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970148
The 7 major diabetic foot ulcers markets reached a value of US$ 3.5 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.94% during 2023-2034.

The diabetic foot ulcers market has been comprehensively analyzed in this report titled "Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic foot ulcers are a common complication of diabetes that occurs when there is damage to the nerves and blood vessels in the feet. This condition can reduce blood flow and decrease sensation in the feet, making them more vulnerable to injury, open sores, or wounds and slower to heal. The common indications of the ailment include swelling, large calluses or cracked heels, blisters, redness, sores, splinters, scrapes, pus, etc. The diagnosis of diabetic foot ulcers is typically made by a review of the patient's medical history, clinical features, and swab tests for secondary infection. Numerous laboratory investigations, including fasting blood sugar, a complete metabolic panel, glycated hemoglobin levels, erythrocyte sedimentation rate, a complete blood count, C-reactive protein, etc., are also utilized to confirm a diagnosis. The healthcare provider may perform X-rays among patients to evaluate the involvement of the bone.

The rising cases of chronic diabetes due to poor glycemic control coupled with the increasing unmet need for effective drugs to address this illness are primarily driving the diabetic foot ulcers market. Furthermore, the growing prevalence of several associated risk factors, such as foot deformities, ill-fitting footwear, underlying peripheral neuropathy, improper foot care, inadequate blood circulation, dry skin, etc., is also propelling the market growth. In addition to this, the escalating utilization of negative-pressure wound therapy, which uses sub-atmospheric pressure to minimize inflammatory exudate and encourage granulation tissue to optimize the physiology involved in wound healing, is creating a positive outlook for the market. Moreover, the inflating adoption of granulocyte-colony stimulating factors (G-CSF) for treating this ailment, since they improve clinical outcomes in patients by increasing the release of neutrophils from the bone marrow and enhancing their function, is also bolstering the market growth. Apart from this, the emerging popularity of tissue-engineered skin substitutes that are designed using living cells, like fibroblasts, keratinocytes, stem cells, etc., to replace or supplement damaged skin and promote wound healing is expected to drive the diabetic foot ulcers market in the coming years.

This report provides an exhaustive analysis of the diabetic foot ulcers market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic foot ulcers and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic foot ulcers market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the diabetic foot ulcers market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the diabetic foot ulcers market

Competitive Landscape:

This report also provides a detailed analysis of the current diabetic foot ulcers marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the diabetic foot ulcers market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the diabetic foot ulcers market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the diabetic foot ulcers market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (​2018-2034​) of diabetic foot ulcers across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of diabetic foot ulcers by age across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of diabetic foot ulcers by gender across the seven major markets?
  • How many patients are diagnosed (​2018-2034​) with diabetic foot ulcers across the seven major markets?
  • What is the size of the diabetic foot ulcers patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of diabetic foot ulcers?
  • What will be the growth rate of patients across the seven major markets?

Diabetic Foot Ulcers: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for diabetic foot ulcers drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic foot ulcers market?
  • What are the key regulatory events related to the diabetic foot ulcers market?
  • What is the structure of clinical trial landscape by status related to the diabetic foot ulcers market?
  • What is the structure of clinical trial landscape by phase related to the diabetic foot ulcers market?
  • What is the structure of clinical trial landscape by route of administration related to the diabetic foot ulcers market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Diabetic Foot Ulcers - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Diabetic Foot Ulcers - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Diabetic Foot Ulcers - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 Diabetic Foot Ulcers - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Diabetic Foot Ulcers - Unmet Needs10 Diabetic Foot Ulcers - Key Endpoints of Treatment
11 Diabetic Foot Ulcers - Marketed Products
11.1 List of Diabetic Foot Ulcers Marketed Drugs Across the Top 7 Markets
11.1.1 Regranex (Becaplermin gel) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zyvox (Linezolid) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fespixon (Centella Asiatica extract) - Oneness Biotech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Easyef (Nepidermin) - Daewoong Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Diabetic Foot Ulcers - Pipeline Drugs
12.1 List of Diabetic Foot Ulcers Pipeline Drugs Across the Top 7 Markets
12.1.1 APO2 - Aposcience
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AUP1602 C - Aurealis Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Bisphosphocin Nu 3 - Lakewood-Amedex Inc
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 allo APZ2 DFU - RHEACELL
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MBN 101 - Microbion Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Diabetic Foot Ulcers - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Diabetic Foot Ulcers - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Diabetic Foot Ulcers - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diabetic Foot Ulcers - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Diabetic Foot Ulcers - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Diabetic Foot Ulcers - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Diabetic Foot Ulcers - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diabetic Foot Ulcers - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Diabetic Foot Ulcers - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diabetic Foot Ulcers - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Diabetic Foot Ulcers - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diabetic Foot Ulcers - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Diabetic Foot Ulcers - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diabetic Foot Ulcers - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Diabetic Foot Ulcers - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diabetic Foot Ulcers - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Diabetic Foot Ulcers - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diabetic Foot Ulcers - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Diabetic Foot Ulcers - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
16 Diabetic Foot Ulcers - Recent Events and Inputs From Key Opinion Leaders
17 Diabetic Foot Ulcers Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Diabetic Foot Ulcers Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information